Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

1.01
-0.0301-2.89%
Volume:131.18K
Turnover:132.85K
Market Cap:15.23M
PE:-0.18
High:1.04
Open:1.04
Low:1.00
Close:1.04
Loading ...

Allarity Therapeutics (ALLR) Has a New Rating from Ascendiant

TIPRANKS
·
29 Jul

Allarity initiated with a Buy at Ascendiant

TIPRANKS
·
28 Jul

Allarity Therapeutics Initiated at Buy by Ascendiant Capital

Dow Jones
·
28 Jul

U.S. RESEARCH ROUNDUP-Cognizant, Lam Research, Sarepta Therapeutics

Reuters
·
28 Jul

Allarity Therapeutics Inc : Ascendiant Capital Markets Initiates Coverage With Buy Rating; Price Target $9

THOMSON REUTERS
·
28 Jul

Allarity Therapeutics Signs New Agreement to Expand DRP® Platform Use in Breast Cancer Solutions

Reuters
·
15 Jul

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

GlobeNewswire
·
15 Jul

Allarity Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CFO Jeffrey S. Ervin

Reuters
·
14 Jul

Allarity appoints Jeff Ervin as CFO

TIPRANKS
·
07 Jul

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

GlobeNewswire
·
07 Jul

Allarity Therapeutics Inc. Announces Australian Patent Acceptance for Stenoparib DRP® Companion Diagnostic

Reuters
·
30 Jun

BRIEF-Allarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer

Reuters
·
27 Jun

Allarity Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
18 Jun

Allarity Therapeutics Appoints Jesper Høiland to Board of Directors, Succeeding Joseph Vazzano

Reuters
·
12 Jun

BRIEF-Allarity Therapeutics Announces Changes To Board Of Directors

Reuters
·
12 Jun

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

GlobeNewswire
·
04 Jun

Allarity Therapeutics Launches New Phase 2 Clinical Trial for Stenoparib in Advanced Ovarian Cancer

Reuters
·
02 Jun

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

TIPRANKS
·
02 Jun

Allarity Therapeutics Q1 EPS $(0.25) Up From $(22.14) YoY

Benzinga
·
10 May

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert

Benzinga
·
01 Apr